

**Packaging**  
REF. N° SH070

50 Tests

**Reaction principle**

The INFECTIOUS MONONUCLEOSIS is a slide agglutination test for the qualitative and semiquantitative detection of heterophile antibodies (HE) specific for infectious mononucleosis.

Latex particles coated with antigenic extract of beef erythrocytes membranes are agglutinated when mixed with samples containing IM heterophile antibodies.

**Reagents composition, Contents and Safety warnings**

1. **Latex Reagent** 1x2.5 ml  
Latex particles coated with bovine erythrocytes extract - Phosphate Buffer pH 7.2 - Sodium Azide 0.95 g/l
2. **Positive Control \* (red cap)** 1x0.5 ml  
Human serum containing anti - IM Antibodies titer  $\geq \frac{1}{4}$  - Sodium Azide 0.95 g/l
3. **Negative Control (blue cap)** 1x 0.5 ml  
Animal serum non reactive with the latex
4. **Reaction Slides** 4
5. **Plastic Stirrers** 25

The product is not classified as hazardous pursuant to the provisions set forth in EC Regulation 1272/2008 (CLP) (and subsequent amendments and supplements).

Further information on the risks to health and / or the environment are given in the data sheet.

**Storage and Stability of Reagents**

Store the kit at 2 - 8°C. (do not freeze)

All the components are stable until the stated expiration date if stored tightly closed and refrigerated

**Preparation and Stability of working solution**

**Latex Reagent** liquid and ready to use  
**Positive Control** liquid and ready to use  
**Negative Control** liquid and ready to use

Swirl the Latex reagent gently before using

Keep reagents at Room Temperature before use

**Samples**

**Fresh serum** (Do not use highly haemolized or lipemic samples)

Samples with presence of fibrin should be centrifuged

Serum may be stored at 2 - 8° C for 7 days, 3 months at - 20°C

**Caution****BIOLOGICAL RISK**

\* Each unit of source material used in the preparation of the Positive Control has been tested by a licensed method and found non reactive for HbsAg and negative for Antibodies to HCV and HIV 1/2.

However no known test can offer complete assurance that products derived from human blood will not transmit Hepatitis, AIDS or other infectious diseases. This product, like all materials of human origin, should be handled as potentially infectious biological material

**Safety Precautions**

For in vitro diagnostic use only

Do not pipette by mouth

Exercise the normal precautions required for handling laboratory reagents

**Qualitative Procedure**

Reagents	1 <sup>a</sup> reactive area Sample	2 <sup>a</sup> reactive area Positive Control	3 <sup>a</sup> reactive area Negative Control
<b>Sample</b>	1 drop (~ 50 µl)	-	-
<b>Positive Control</b>	-	1 drop (~ 50 µl)	-
<b>Negative Control</b>	-	-	1 drop (~ 50 µl)
<b>Latex reagent</b>	1 drop (~ 50 µl)	1 drop (~ 50 µl)	1 drop (~ 50 µl)

Mix the two drops with a stirrer, spreading them over the entire surface of the circle. (Use one different stirrer for each reactive area).

Place the slide on a mechanical rotator at 80 - 100 r.p.m. for 2 minutes.

**False positive results could appear if the test is read later than two minutes.**

**Results**

The presence of agglutination within 2 minutes indicates an Antibodies concentration  $\geq 1/28$  (according Davidson method)

**Positive samples should be titrated (see semiquantitative procedure)**

**Semiquantitative Procedure**

Prepare serial dilutions of the sample with Saline Solution and proceed, for each dilution, as in the qualitative method.

The titre is defined as the highest dilution showing a positive result

**Performance Characteristics****A. ANALYTICAL SENSITIVITY**

1/28 (according Davidson method)

**B. PROZONE EFFECT**

No prozone effect was detected up to titre = 1/256

**C. DIAGNOSTIC SENSITIVITY**

100%

**D. DIAGNOSTIC SPECIFICITY**

100%

**E. INTERFERENCES**

1. Haemoglobin till to 10 g/l does not interfere
2. Bilirubin till to 20 mg/dl does not interfere
3. Lipids till to 10 g/l do not interfere
4. Rheumatoid factors till to 300 IU/ml does not interfere
5. Other substances may interfere <sup>7</sup>

**Quality control**

Positive and Negative Control Sera should be run with each serie.

Their results should be compared with those of unknown specimen to distinguish possible agglutination

**Limitations of the procedure**

1. False positive results may be obtained in some geographical areas where the "horse serum" is used as a prophylactic measure (vaccination)
2. Patients suffering from leukemia, Burkitt's lymphoma, pancreatic carcinoma, viral hepatitis, CMV infectious and others, can result false positive reactions
3. False negative results have been reported in cases of IM, which persistently remain seronegative for IM heterophile antibodies or as a consequence of a delay IM heterophile antibodies response.  
In this case, repeat testing samples obtained at intervals of several days.
4. Clinical diagnosis should not be made on findings of a single test result, but should integrate both clinical and laboratory data

**Bibliography**

1. Summaya C V et al: Manual of Clinical Laboratory Immunology 4<sup>th</sup> ed. 568 Washington DC ASM (1992)
2. Merlin J. R. et al: Human Pathol 17:2 (1986)
3. Paul J. R. et al: AM. J. Med Sci 183, 90 (1932)
4. Andiman W A: Manual of Clinical Laboratory Immunology 3<sup>rd</sup> ed. 509 Washington DC AMS (1986)
5. Henie W. et al: Huma Path 5, 551 (1974)
6. Barbara A., Levey et al: Journal of Clinical Microbiology 11, 256 - 262 (1980)
7. Young D S: Effects of drugs on clinical laboratory test 4<sup>th</sup> ed. AACCC Press 1995

